Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus MIUDELLA.
ENOVID-E vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive